Anteris Technologies Ltd (AVR.AX)
Anteris Technologies Ltd operates in the Medical - Devices industry of the Healthcare sector, headquartered in Toowong, QLD, AU. The stock last traded at $12.40, down 3.50% on the session, giving a market capitalisation of $1.21B. Its beta of 0.73 implies it has historically moved less than the broad market.
Anteris Technologies Ltd is a firm specializing in the structural heart domain. It is responsible for the production and distribution of ADAPT, a product based on regenerative tissue technology. The company is also actively involved in advancing DurAVR™, an innovative 3D single-component aortic valve specifically designed for treating aortic stenosis. Additionally, Anteris allocates resources to the research and development of regenerative medicines. Founded in 1999, the enterprise was formerly known as Admedus Limited until it rebranded to Anteris Technologies Ltd in May 2020. Its primary operations are conducted from its base in Toowong, Australia.
Anteris Technologies Ltd is most often compared with the following Healthcare names: